TNF and histoplasmosis: The sensitivity analysis excluding data from the 2 groups known to be exclusively using etanercept, a TNF-ɑ inhibitor with arguably lesser immunosuppressive potential, demonstrated that the incidence rate of histoplasmosis increased to 54.88/100,000 patients (Fig. 3).